systemic amyloidosis

Systemic amyloidosis often affects the gastrointestinal tract and may result in this condition.

Primary Systemic Amyloidosis, in which a human body produces "bad proteins"

These bleedings are not associated with systemic amyloidosis.

The different types of systemic amyloidosis are sometimes classified as primary, secondary or familial (hereditary).

For example, purpura is present early in the disease in approximately 15% of patients with primary systemic amyloidosis.

A proposed staging system for primary systemic amyloidosis based on these serum levels requires independent and prospective confirmation.

Primary amyloidosis (also called AL) is the most common type of systemic amyloidosis.

You are more likely to develop secondary systemic amyloidosis if you have a long-term infection or inflammation.

Another disease, senile systemic amyloidosis, clogs the heart tissues of 10 to 15 percent of people over age 80.

It is contrasted to systemic amyloidosis, and it can be caused by several different types of amyloid.

Secondary systemic amyloidosis is a disorder in which abnormal proteins build up in tissues and organs.

Recently, biochemical analyses have shown that several different types of amyloid fibril protein exist in systemic amyloidosis.

Senile systemic amyloidosis was determined to be the primary cause of death for 70% of supercentenarians who have been autopsied.

Examples are reactive systemic amyloidosis and secondary cutaneous amyloidosis.

(Senile systemic amyloidosis is also associated with transthyretin aggregation.)

Senile systemic amyloidosis, a highly related cardiomyopathy, results from the aggregation of wild-type transthyretin exclusively.

Minor causes of chronic adrenal insufficiency are systemic amyloidosis, fungal infections, hemochromatosis, and sarcoidosis.

Thus, Senile systemic amyloidosis and familial amyloid polyneuropathy are often treatable diseases that are misdiagnosed.

Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with primary systemic amyloidosis.

Primary systemic amyloidosis (AL amyloidosis or just primary amyloidosis) is a disease that involves the mesenchymal tissue, the tongue, heart, gastrointestinal tract, and skin.

In April 2000, he was diagnosed with primary systemic amyloidosis, a disease that produces an abnormal protein that collects in tissues and interferes with the function of organs.

Complications such as hyperviscosity syndrome, symptomatic sensorimotor peripheral neuropathy, systemic amyloidosis, renal insufficiency, or symptomatic cryoglobulinemia were also suggested as indications for therapy.

Dispenzieri A, Lacy MQ, Zeldenrust SR, et al.: The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.

Gertz MA, Li CY, Shirahama T, et al.: Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobulin light chain).

Dispenzieri A, Kyle RA, Lacy MQ, et al.: Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.